Verition Fund Management
SYRS

Verition Fund Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Verition Fund Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,320
Closed -$22K – 3248
2022
Q2 		$22K Buy
+2,320
New +$21.7K ﹤0.01% 2210

Other funds holding SYRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Verition Fund Management's SYRS Position: Q3 2022 in Review

Verition Fund Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2022, closing a stake of 2,320 shares — an estimated $22K sold.

Verition Fund Management first reported a position in SYRS in Q2 2022 and held it in 1 quarter. The position peaked at $22K in Q2 2022. 53 funds tracked by Wall St. Rank hold SYRS as of Q3 2022.

  • Verition Fund Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Verition Fund Management sold 2,320 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $22K.
  • Verition Fund Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Verition Fund Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $22K in Q2 2022.
  • 53 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Verition Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.